


Efficiency of the CD8⁺ T cell response to persistent viral infection

Becca Asquith

Background: CD8⁺ T cells



- Immune cells
- Help control virus infection
- Kill virus-infected cells

Also known as cytotoxic
T lymphocytes (CTL)

Research Questions

**CD8⁺ T cell Efficiency:
(in humans, *in vivo*)**

Quantification.

Determinants.

Improvement.

Determinants of CD8⁺ T Cell Efficiency

What makes a good CD8⁺ T cell response?


What makes a good HLA class I molecule?

Background: HLA class I molecules

- Essential for T cell recognition

- Display fragments of intracellular proteins

- HLA class I molecule + viral epitope is a signature of an infected cell



Different people have different HLA alleles
→ bind different viral epitopes
→ different outcomes of infection

Determinants of CD8⁺ T Cell Efficiency

What makes a good HLA class I molecule?

- Protein specificity
- KIRs

What constitutes a protective HLA class I molecule?

Hypothesis:

Specificity is a determinant of HLA “protectiveness”

Epitope prediction software (Metaserver)

Validated for known epitopes: HIV, HCV, EBV etc

HIV: 661 epitopes amongst 122,339 9-mers

SYFPEITHI: 148 epitopes amongst 782,442 9-mers

Sensitivity: 80%. Specificity: 97.4%

Significantly better than the best existing software
($P < 0.00001$)

Epitope prediction software


Tested for HTLV-1:

Synthesised 200 HTLV-1 peptides

Measured binding affinity (ELISA with a conformation dependent anti-HLA antibody)

A*0201 A*2402 B*0701 B*3501

Epitope prediction software



$P=3 \times 10^{-25}$

MacNamara et al
PLoS Comp Biol
2009

Epitope prediction software

**Metaserver predicts HLA class I
epitopes & binding affinity with
good accuracy**

MacNamara et al PLoS Comp Biol 2009

<http://web.bioinformatics.ic.ac.uk/metaserver/>

<http://www1.imperial.ac.uk/medicine/people/b.asquith/>

Human T Lymphotropic Virus (HTLV-1)

Infects 10-20 million

95% Asymptomatic carrier (AC)



1-2% HAM/TSP




2-5% Adult T cell Leukemia

HLA-A*02, C*08 protective
B*54 detrimental


Method

Cohort of HTLV-I infected individuals from Japan

- 202 asymptomatic carriers (ACs)
- 230 HAM/TSP patients



Do protective HLA molecules bind different proteins?




**Protective HLA class I molecules bind
HBZ strongly**


Do HAM/TSPs & ACs bind different proteins?

$P=0.00005$

Strength of HBZ binding




HLA-A



HLA-B

Asymptomatic carriers possess HLA molecules that bind HBZ strongly
*Remove individuals with A2 or B54.
result still holds*

Does HLA specificity determine proviral load?



Strong binding of HBZ is associated with a low proviral load

What makes a good HLA class I molecule?

"best"





"worst"

HBZ
gag
p21
pol
p27
tax
rex
p30
p13
pro
p12
env


Bears no relationship to
immunodominance
hierarchy

HBZ-specific CD8⁺ T cells exist & are functional

IFN γ ELISpot



CD107a staining




Aileen Rowan


HBZ-specific CTL clone can kill infected cells

Chromium release

HLA matched




HLA mismatched



Aileen Rowan

Why HBZ?

HTLV-I
provirus-carrying
cell



Why HBZ?

HBZ inhibits expression of
other HTLV-I genes
=> Evade immune response

HBZ expression drives
infected cell proliferation



HBZ-specific
CTL

Proviral load increases.

- In HTLV-1 specificity is an important determinant of CD8⁺ T cell efficiency
- The most efficient responses are specific for HBZ

MacNamara et al **PLoS Pathogens** 2010

Determinants of CD8⁺ T Cell Efficiency

What makes a good HLA class I molecule?

- Specificity
- KIRs

Background: KIRs

Killer Immunoglobulin-like Receptors

Activating & inhibitory isoforms


Expressed on NK cells & a subset of T cells

Bind HLA class I molecules

KIR2DL2

Inhibitory receptor

Binds HLA-C molecules



Hypothesis:

Killer immunoglobulin–like receptors (KIRs) influence HLA class I-mediated immunity

HCV

Infects 170 million

 30% Spontaneous
viral clearance


 70% Chronic
infection

HLA-B57 protective

Cohort: N=702

HTLV-1

Infects 10-20 million

 95% Asymptomatic
carrier (AC)

 1-2% HAM/TSP

 2-5% Leukemia

A02, C08 protective

B54 detrimental



Cohort: N=432

Method: immunogenetics

Hypothesis: KIR genotype determines efficiency of the HLA-restricted response

- Hepatitis C Virus (HCV) & Human T Lymphotropic Virus (HTLV)
- Known protective & detrimental HLA class I molecules
- Stratify cohort by KIR genotype
- Investigate how the protective/ detrimental effect of the HLA molecules is altered


HCV:KIR2DL2 enhances B*57 protective effect




KIR2DL2 enhancement strengthens with increasing copy number

HTLV-1: *KIR2DL2* enhances protective effect of C*08



Outcome of infection





Proviral load (AC)





HTLV-1: *KIR2DL2* enhances detrimental effect of *B*54*







Whole cohort
 $P=0.00005$



KIR2DL2+
 $P=0.00006$

Asymptomatic carriers bind HBZ significantly more strongly

MacNamara et al PLoS Path 2010



KIR2DL2-
 $P=0.06$

KIR2DL2 enhances protective effect of binding HBZ by multiple HLA class I molecules

KIR2DL2: interim summary

***KIR2DL2* enhances protective and detrimental HLA class I-mediated antiviral immunity**

HTLV-1

- *C*08*: disease status
- *C*08*: proviral load
- *B*54*: disease status
- *B*54*: proviral load
- HBZ binding: disease status

HCV

- *B*57*: viral clearance
- *B*57*: viral load


Explanation of why HLA don't always work

Other KIR:HLA studies

- Khakoo *et al.* (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. *Science*
- Martin *et al.* (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. *Nature Genetics*
- Lopez-Vazquez *et al.* (2005) Protective effect of the HLA-Bw4I80 epitope and the KIR3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. *J Infect Dis*
- Martin *et al.* (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. *Nature Genetics*

Etc etc ...

Direct NK killing of virus infected cell



Predict:


- 1) KIR with its ligand would have an effect on outcome
- 2) HLA class I molecules that do not bind the KIR would have no effect
- 3) Effect would be unidirectional (consistently protective or consistently detrimental)

Our observations quite different ...

Predict	Observe
KIR with its ligand would have an effect on outcome	
HLA class I molecules that do not bind the KIR would have no effect	
Effect would be unidirectional	

Postulated Mechanisms

(i)



What next?

- How general is KIR2DL2-enhancement of adaptive immunity?
- What is the mechanism?
 - Does KIR2DL2 enhance the efficiency of CD8⁺ T cells?
 - Does KIR2DL2 enhance the survival of CD8⁺ T cells?

Summary: Determinants of efficiency I

Used on a...
to...
pr...

TAKE HOME 1

- General approach to investigate determinants of immune protection
- Protein specificity an important determinant of protection
- Immunogenicity is not

binding
pol

HBZ
gag
p21
pol
p27
tax
rex
p30
p13
pro
p12
env

"worst"

Summary: Determinants of efficiency II

TAKE HOME 2

- An “innate” receptor is enhancing HLA class I associations
- Potential explanation for incomplete penetrance of protective/ detrimental HLA traits
- Novel role for KIR in adaptive immunity?

Ongoing projects

Can non-lytic CD8+ T cell effector mechanisms select for viral escape variants?

How can we estimate diversity (viral clones, TCR, fish....)?

How can we understand KIR-associated polymorphisms in HIV-1?

Acknowledgements: my team

Marjet Elemans

Chris Gkekas

Ulrich Kadolsky

Aidan MacNamara

Nafisa-Katrin Seich al Basatena

Danny Laydon

Acknowledgements: collaborators

Jacquie Astemborski

Charles Bangham

Mary Carrington

Shayne Donfield

Charlie Edwards

Arnaud Florins

Hiroshi Fujiwara

Jim Goedert

Silva Hilburn

Miti Kaur

Salim Khakoo

Greg Kirk

Nikki Klatt

Agnès Lezin

Marc Lipsitch

Angela Mclean

Heather Niederer

Stéphane Olindo

Mitsuhiro Osame

Aileen Rowan

Guido Silvestri

Koichiro Suemori

Graham Taylor

Rod Thiébaud

Chloe Thio

Emma Thompson

Koichiro Usuku

Alison Vine

Luc Willems

Aviva Witkover

Masaki Yasukawa

Thanks for helpful discussions:

John Trowsdale

James Traherne

José Borghans

Can Keşmir

Keith Gould



Pioneering research
and skills



RESEARCH
COUNCILS UK

wellcometrust

Epitope prediction:

T-cell epitope prediction: rescaling can mask biological variation between MHC molecules.

MacNamara A, Kadolsky U, Bangham CR, Asquith B. PLoS Comput Biol. 2009 Mar;5(3):e1000327.

HBZ:

HLA class I binding of HBZ determines outcome in HTLV-1 infection.

Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CR, Asquith B. PLoS Pathog. 2010 Sep 23;6(9):e1001117.

In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.

Hilburn S, Rowan A, Demontis MA, MacNamara A, **Asquith B**, Bangham CR, Taylor GP.
J Infect Dis. 2011 Feb 15;203(4):529-36.

KIRs:

KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection.

Seich AI Basatena NK, Macnamara A, Vine AM, Thio CL, Astemborski J, Usuku K, Osame M, Kirk GD, Donfield SM, Goedert JJ, Bangham CR, Carrington M, Khakoo SI, Asquith B. PLoS Pathog. 2011 Oct;7(10):e1002270.

In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection.

O'Connor GM, Seich AI Basatena NK, Olavarria V, MacNamara A, Vine A, Ying Q, Hisada M, Galvão-Castro B, Asquith B, McVicar DW. Hum Immunol. 2012 Aug;73(8):783-7.

Links to related papers

Some recent reviews:

[HTLV-1: Persistence and pathogenesis.](#)

Cook LB, Elemans M, Rowan AG, Asquith B.
Virology. 2013 Jan 5;435(1):131-40.

[The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter?](#)

Elemans M, Seich AI Basatena NK, Asquith B.
PLoS Comput Biol. 2012;8(2):e1002381.